Transforming Lives

Through a new class of safe, durable cancer treatments.

In The News

    • MAR 21 2018

    Fox Chase Cancer Center Researchers Uncover ONC201 Immune-oncology Effects

    “Immune cell activation in the tumor and inhibition of metastasis with an oral, infrequently administered and well tolerated small molecule provides an attractive treatment option for patients. Immune activation is recognized as an important requirement to achieve durable and complete remissions in conjunction with standard-of-care therapies,” said El-Deiry. “We discovered ONC201 through its ability to

    • JAN 25 2018

    OncologyTube interviewed Dr. Anderson to talk about his ONC201 trial

    In the videos below, Dr. Peter Anderson talks about ONC201 and his Phase II – Neuroendocrine Tumors (NCT03034200) at The Cleveland Clinic. The clinical trial is evaluating ONC201 in patients with neuroendocrine tumors. These tumors are known to overexpress DRD2, the target that ONC201 utilizes to drive its anti-cancer effects. Dr. Peter Anderson is the